Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Brief Title

Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Official Title

Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Brief Summary

      Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the
      disease, but there is a food additive that includes acetate . We suggest an early treatment
      with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any
      case the treatment will be stopped at the age of 22 months, when myelinization is ended.
    



Study Type

Interventional


Primary Outcome

brain MRI at the end of the study


Condition

Canavan Disease

Intervention

GTA (Glyceryl triacetate)


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Dietary Supplement

Estimated Enrollment

1

Start Date

March 2008


Primary Completion Date

August 2008

Eligibility Criteria

        Inclusion Criteria:

          -  clinical diagnosis of Canavan disease

        Exclusion Criteria:

          -  Age above 18 months
      

Gender

All

Ages

N/A - 18 Months

Accepts Healthy Volunteers

No

Contacts

Gheona Alterescu, M.D., 972-2-6666435, [email protected]

Location Countries

Israel

Location Countries

Israel

Administrative Informations


NCT ID

NCT00724802

Organization ID

canavangta



Study Sponsor

Shaare Zedek Medical Center


Study Sponsor

Gheona Alterescu, M.D., Principal Investigator, Shaare Zedek Medical Center


Verification Date

June 2011